Further ultrasonographic studies in horses and people with connective tissue disease might determine the impact of MDB action on subarachnoid space width and correlation with clinical symptoms, i.e. headaches and craniocervical neurological symptoms. This evidence concerns the gene ABR and connective tissue disorder.